On this page
Constitutional mismatch repair deficiency
This condition dramatically increases the risk of multiple cancers beginning in childhood, particularly brain tumours and bowel cancer. It occurs when a child inherits pathogenic variants in both copies of a mismatch repair gene from carrier parents. Affected individuals require intensive surveillance from diagnosis onwards.
Available at Jeen Health
Clinical tests that include this
Overview
Constitutional mismatch repair deficiency (CMMRD) represents one of the most severe cancer predisposition syndromes recognised in clinical genetics. Unlike many hereditary cancer conditions that increase risk in adulthood, CMMRD typically manifests with malignancies during childhood or adolescence [PMID:25186627]. The condition arises when both copies of a mismatch repair gene - most commonly MLH1, MSH2, MSH6, or occasionally PMS2 - carry pathogenic variants, completely eliminating the cell's ability to correct DNA replication errors effectively.
During normal cell division, the mismatch repair system acts as quality control, catching and fixing copying mistakes. Complete failure of this system causes replication errors to persist and build up throughout the genome at a markedly accelerated pace, driving malignant transformation across multiple tissue types [PMID:24728327]. This widespread genomic instability distinguishes CMMRD from other cancer syndromes and accounts for the exceptionally high lifetime cancer burden observed in affected individuals.
CMMRD remains rare, with exact prevalence difficult to establish due to its severity and the relatively recent molecular characterisation of the condition. Most cases are identified through family history when parents are known carriers of Lynch syndrome-associated variants, or following an unexpectedly early cancer diagnosis in a child. Recognition of CMMRD has important implications not only for the affected individual but also for family members who may be heterozygous carriers at elevated risk for adult-onset malignancies.
Symptoms & clinical features
The clinical presentation of CMMRD is characterised by multiple primary cancers developing at unusually young ages, often before the age of 18 years. Brain tumours represent the most frequent malignancy, particularly high-grade gliomas and medulloblastomas, which may present with headaches, seizures, visual disturbances, or progressive neurological deficits [PMID:25186627]. Gastrointestinal cancers, especially colorectal carcinomas, constitute another major category and can manifest with altered bowel habits, rectal bleeding, abdominal pain, or unexplained weight loss - symptoms that clinicians might not immediately associate with malignancy in a paediatric patient.
Haematological malignancies, particularly non-Hodgkin lymphomas and acute leukaemias, occur with increased frequency and may present with fatigue, recurrent infections, easy bruising, or lymph node enlargement. Beyond malignancies, many individuals display distinctive physical features that can aid clinical recognition. Café-au-lait spots - flat, coffee-coloured skin patches - often number more than the typical diagnostic threshold for neurofibromatosis type 1, leading to initial diagnostic confusion. Some affected children exhibit subtle dysmorphic facial features or growth abnormalities.
The cancer spectrum in CMMRD extends beyond these common presentations to include endometrial, ovarian, urinary tract, and small bowel tumours. A notable characteristic of the syndrome is the tendency to develop multiple independent primary cancers throughout life, rather than a single malignancy. Some individuals may also experience benign colorectal polyps from childhood onwards, detected during surveillance colonoscopy. The wide phenotypic variability means that whilst some children present with aggressive cancers in early childhood, others may not develop their first malignancy until adolescence, though this represents the milder end of the clinical spectrum.
Video: Is cancer in your genes?
Affected organs
The organs most vulnerable to malignant transformation in CMMRD reflect those with high cellular turnover rates, where unrepaired replication errors accumulate most rapidly. The central nervous system bears a particularly heavy burden, with brain tumours developing in a substantial proportion of affected individuals. These malignancies arise throughout the brain, including the cerebral hemispheres, brainstem, and cerebellum, with glioblastomas and medulloblastomas being especially characteristic [PMID:24728327].
The gastrointestinal tract represents another primary target organ system, with the colon and rectum being particularly susceptible. Colorectal cancers in CMMRD typically develop decades earlier than sporadic cases, often presenting in childhood or adolescence. The small intestine may also develop adenocarcinomas, though less frequently than the large bowel. The haematopoietic system is notably affected, with lymphomas arising in lymph nodes, bone marrow, and occasionally extranodal sites. In female patients, the reproductive organs - particularly the endometrium and ovaries - face elevated cancer risk, though these malignancies tend to emerge somewhat later than brain and bowel tumours. The urinary tract, skin, and other organ systems can also be affected, reflecting the systemic nature of the underlying genomic instability that characterises this syndrome.
Risks & severity
Constitutional mismatch repair deficiency represents one of the most penetrant cancer predisposition syndromes, with very high cumulative cancer risk evident by early adulthood in published cohort studies [PMID:25186627]. The median age at first cancer diagnosis typically falls within the first two decades of life, with some children developing malignancies before age 5 years. This stands in stark contrast to Lynch syndrome, where heterozygous carriers of the same genes face elevated cancer risks primarily in adulthood, illustrating the profound impact of complete mismatch repair deficiency.
The severity of CMMRD extends beyond the high overall cancer risk to encompass the aggressive nature of individual tumours and the propensity for multiple primary cancers. Many affected individuals will develop two, three, or more independent malignancies during their lifetime, each requiring separate treatment and carrying its own morbidity. Brain tumours in CMMRD often prove particularly challenging to manage, with high-grade gliomas carrying poor prognoses despite intensive therapy. Gastrointestinal cancers may present at advanced stages due to the unexpected nature of malignancy in paediatric patients. The compounding effects of multiple cancer diagnoses, each necessitating surgery, chemotherapy, or radiotherapy, create substantial cumulative health burdens. Long-term survivors face treatment-related complications including secondary malignancies induced by radiation exposure, a particularly concerning issue given the underlying genomic instability. The psychological and social impacts on affected children and their families prove equally significant, with the knowledge of ongoing high cancer risk affecting quality of life and life planning throughout childhood and into adulthood.
Genetic causes
Constitutional mismatch repair deficiency occurs when both copies of a mismatch repair gene carry pathogenic variants, eliminating the cell's capacity to correct DNA replication errors effectively. The genes most commonly implicated are MLH1, MSH2, MSH6, and PMS2, each encoding a protein component of the mismatch repair machinery. MLH1 produces a protein that coordinates the correction of mistakes arising when cellular DNA is duplicated; biallelic pathogenic changes abolish this quality-control mechanism entirely. MSH2 encodes a different component that spots mismatched nucleotides and initiates the repair cascade - when both gene copies harbour damaging variants, cells fail to recognise these replication errors before they solidify into permanent mutations.
MSH6 generates yet another element critical for preserving genomic fidelity by detecting and facilitating repair of copying mistakes. Although MSH6-related CMMRD may occasionally show a somewhat attenuated clinical picture compared to deficiency of MLH1 or MSH2, affected individuals still face markedly elevated cancer risks from childhood onwards. These proteins normally collaborate in multi-component assemblies: MSH2 joins with MSH6 to identify base-pairing mistakes and small insertions or deletions, whilst MLH1 partners with PMS2 in downstream repair coordination.
When mismatch repair is completely absent, errors made during DNA copying remain uncorrected and multiply with each cell division. Affected cells develop a dramatically accelerated mutation rate, manifesting as a hypermutator phenotype. Genomic instability becomes evident at the molecular level as microsatellite instability - expansions or contractions of repetitive DNA sequences scattered across the genome - which serves as a detectable molecular signature in tumour tissue from affected individuals. This rapid mutation accumulation drives the early onset and multiple primary cancers characteristic of CMMRD, as cancer-promoting genes become activated and protective tumour suppressor genes lose function at unusually high rates across diverse tissue types.
- MLH1 mutL homolog 1The *MLH1* gene provides instructions for a protein essential in DNA mismatch repair, a crucial process that corrects errors occurring during DNA replication to maintain genomic integrity.
- MSH2 mutS homolog 2The MSH2 gene provides instructions for a protein that is essential for DNA mismatch repair, a critical process for maintaining genomic stability and preventing cancer.
- MSH6 mutS homolog 6The MSH6 gene provides instructions for a protein critical to DNA mismatch repair, playing a vital role in correcting errors that occur during DNA replication.
Inheritance pattern
Constitutional mismatch repair deficiency follows an autosomal recessive inheritance pattern, meaning affected individuals inherit one pathogenic variant from each parent. Both parents are typically heterozygous carriers - they possess one functional and one non-functional copy of a mismatch repair gene - which places them in the category of Lynch syndrome. Carrier parents generally remain asymptomatic during childhood and face elevated cancer risks primarily in adulthood, a much milder phenotype than their affected children who completely lack mismatch repair capacity [PMID:25186627].
When both parents carry a pathogenic variant in the same mismatch repair gene, each pregnancy carries a 25% chance of producing a child with CMMRD, a 50% chance of producing a carrier child, and a 25% chance of a child inheriting neither variant. Siblings of an affected child have a one-in-four risk of also having CMMRD and a two-in-four chance of being carriers who will face Lynch syndrome-associated cancer risks. Extended family members may also be carriers, particularly if Lynch syndrome has been identified in previous generations. Genetic counselling proves essential for families navigating these risks, as carrier testing and prenatal or preimplantation genetic diagnosis may be options for family planning. The recessive nature of CMMRD means it can appear unexpectedly in families without a known history of childhood cancer, particularly when parents are distantly related or both come from populations with higher carrier frequencies for specific variants. Recognition of CMMRD in a child prompts cascade testing throughout the extended family to identify carriers who may benefit from Lynch syndrome surveillance protocols.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of constitutional mismatch repair deficiency typically begins with clinical suspicion triggered by an unusually early cancer diagnosis, multiple primary cancers in a child or young adult, or suggestive physical features such as numerous café-au-lait spots combined with a cancer diagnosis. Initial investigations often include tumour testing for microsatellite instability (MSI) or immunohistochemistry to assess mismatch repair protein expression - complete absence of staining for one or more mismatch repair proteins in tumour tissue strongly suggests CMMRD [PMID:24728327]. However, definitive diagnosis requires germline genetic testing demonstrating biallelic pathogenic variants in a mismatch repair gene.
Within the NHS Genomic Medicine Service framework, suspected CMMRD cases warrant referral to clinical genetics services through appropriate pathways. The relevant PanelApp resources include testing panels for hereditary cancer syndromes and constitutional mismatch repair deficiency specifically. Genetic testing typically employs comprehensive genomic approaches including sequencing and copy number analysis to detect point mutations, small insertions or deletions, and larger structural rearrangements affecting MLH1, MSH2, MSH6, or PMS2. Once a molecular diagnosis is established, genetic counselling helps families understand inheritance patterns, recurrence risks, and implications for extended family members who may benefit from cascade carrier testing. The diagnosis triggers intensive surveillance protocols and access to specialist multidisciplinary care teams experienced in managing paediatric cancer predisposition syndromes.
Management & lifestyle
Management of constitutional mismatch repair deficiency centres on intensive, lifelong cancer surveillance aimed at detecting malignancies at the earliest possible stage when treatment outcomes are most favourable. Surveillance protocols typically commence from diagnosis or early childhood and involve multiple imaging and endoscopic procedures coordinated by specialist teams. Brain imaging with MRI generally occurs every six months to detect central nervous system tumours before they cause neurological symptoms. Gastrointestinal surveillance includes colonoscopy, often with intervals of one to two years beginning in childhood, to identify and remove precancerous polyps and detect colorectal cancers early [PMID:25186627]. Upper gastrointestinal endoscopy may also form part of the surveillance programme.
Additional surveillance measures may include abdominal ultrasound or MRI to screen for urinary tract malignancies, and haematological monitoring for leukaemias and lymphomas. Female patients require gynaecological surveillance from late adolescence or early adulthood to detect endometrial and ovarian cancers. Whole-body MRI protocols are increasingly employed at some specialist centres to screen multiple organ systems simultaneously. When cancers are diagnosed, treatment follows standard oncological protocols adapted to the paediatric or young adult setting, though management can prove particularly challenging given the underlying genomic instability and elevated risk of treatment-related secondary malignancies from radiation therapy.
Risk-reducing surgical interventions, such as prophylactic colectomy, may be considered in specific circumstances, though decisions require careful individualised assessment balancing cancer risk against surgical morbidity in a young person. Access to psychological support for affected individuals and their families proves crucial, given the ongoing burden of surveillance, potential cancer diagnoses, and quality-of-life impacts. Within the UK, care is typically coordinated through specialist paediatric oncology and clinical genetics services working collaboratively. Genetic counsellors provide essential support in helping families understand the condition, navigate surveillance recommendations, and make informed decisions about testing at-risk relatives. Research participation may be encouraged, as the rarity of CMMRD means prospective studies remain essential for refining surveillance protocols and exploring emerging therapeutic approaches.
UK care pathway
Within the NHS Genomic Medicine Service, suspected constitutional mismatch repair deficiency typically prompts referral to regional clinical genetics services. Testing utilises PanelApp virtual gene panels relevant to cancer predisposition syndromes and constitutional mismatch repair deficiency specifically, accessed through the NHS Genomic Medicine Service testing directory. The relevant R-code pathway facilitates appropriate genetic testing for individuals meeting clinical criteria - typically those with early-onset cancers, multiple primary cancers in childhood, or suggestive features such as café-au-lait spots combined with malignancy.
Following molecular diagnosis, affected individuals gain access to specialist multidisciplinary teams experienced in managing childhood cancer predisposition. This includes paediatric oncologists, clinical geneticists, genetic counsellors, and relevant surgical specialists who collaboratively develop personalised surveillance and management plans. Genetic counselling services provide essential support for families navigating the inheritance implications, helping coordinate cascade testing for at-risk relatives who may be carriers. The genetic counsellor can explain what carrier status means for adult-onset cancer risks associated with Lynch syndrome and discuss reproductive options for future family planning. Regular review within specialist services ensures surveillance protocols adapt to emerging evidence and individual patient circumstances throughout childhood and into adult care.
Frequently asked questions
How is CMMRD different from Lynch syndrome if they involve the same genes?
Lynch syndrome occurs when someone inherits one faulty copy of a mismatch repair gene, leaving the other copy functioning normally. This increases cancer risk mainly in adulthood. CMMRD occurs when both copies are faulty, completely eliminating mismatch repair and causing cancers to develop much earlier, typically in childhood.
Will my other children have CMMRD if one child is diagnosed?
Each pregnancy has a 25% chance of producing a child with CMMRD when both parents are carriers. Siblings can be tested to determine if they are affected, carriers, or have inherited neither variant. Genetic counselling can help families understand these risks and explore options for future pregnancies.
How often will my child need cancer surveillance?
Surveillance protocols are intensive and typically include brain MRI every six months, colonoscopy every one to two years, and additional screening depending on individual risk factors. The exact schedule is personalised by the specialist team based on your child's age, previous findings, and emerging evidence.
Can anything be done to prevent cancers from developing?
Whilst surveillance cannot prevent cancers, it aims to detect them at the earliest possible stage when treatment is most effective. Some families may discuss risk-reducing surgeries such as colectomy with their medical team, though such decisions require careful consideration of benefits and risks in a young person.
Should family members be tested even if they have no symptoms?
Yes, testing parents and siblings is important. Parents are typically carriers with Lynch syndrome who need adult cancer surveillance. Siblings may be affected and require childhood surveillance, or may be carriers who will need monitoring from adulthood. Genetic counselling helps coordinate appropriate family testing.
References
- Aronson M, Colas C, Shuen A. Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. Journal of medical genetics. 2022. PMID: 33622763
- Ercan AB, Aronson M, Fernandez NR. Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study. The Lancet. Oncology. 2024. PMID: 38552658
- Hansford JR, Das A, McGee RB. Update on Cancer Predisposition Syndromes and Surveillance Guidelines for Childhood Brain Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 38573059
- Rafei H, DiNardo CD. Hereditary myeloid malignancies. Best practice & research. Clinical haematology. 2019. PMID: 31203998
- Adam MP, Bick S, Mirzaa GM. Lynch Syndrome. 1993. PMID: 20301390
- Abedalthagafi M. Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies. Oncotarget. 2018. PMID: 30459937
- van der Klift HM, Mensenkamp AR, Drost M. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome. Human mutation. 2016. PMID: 27435373
- Wimmer K, Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica. 2010. PMID: 20442441